Drug combinations are a promising strategy to increase killing efficiency and to decrease the 24 likelihood of evolving resistance. A major challenge is to gain a detailed understanding of how 25 drugs interact in a dose-specific manner, especially for interactions involving more than two 26 drugs. Here we introduce a direct and intuitive visual representation that we term "interaction 27 landscapes". We use these landscapes to clearly show that the interaction type of two drugs 28 typically transitions smoothly from antagonism to no interaction to synergy as drug doses 29
Introduction 43 44
Combination therapy is widely used to treat a number of chronic health issues such as cancer 45
[1, 2] , HIV [3, 4] , hypertension [5] or multidrug resistant bacterial infections [6, 7] . 46
Understanding the effects of these drug combinations and interactions among drugs is a major 47 clinical concern and active research area [8] [9] [10] [11] [12] [13] [14] . A promising strategy for combatting the 48 evolution of drug resistance is to use drugs in combination by effectively leveraging 49 interactions. However, a detailed understanding of how three drugs interact in a dose-specific 50 manner is challenging to examine and visualize. Gaining this understanding has importance 51 both for devising optimal treatments and for leveraging selection pressure to combat evolution 52 of resistance. 53
54
Measures for interactions are often evaluated based on a coarse-grained categorization of 55 three interaction types: additive (no interaction), synergistic (combined effect greater than 56 expected based on single-drug effects), and antagonistic (combined effect less than expected 57 based on single-drug effects). Synergistic drug combinations, in which combining drugs 58 enhances the effects of the individual drugs, are commonly prescribed for patients because 59 they maximize efficacy at lower doses. However, previous work indicates that antagonism may 60 be more beneficial for slowing down the rate of resistance evolution to the component drugs 61 [10, 14] , because it creates more complex or rugged fitness landscapes. Thus, simply knowing 62 how interactions deviate from additivity towards synergy or antagonism is potentially a 63 7 and low drug concentrations result primarily in net interactions that are additive or antagonistic 130 (Fig. S1 ). Synergistic DA and E3 interactions are mostly observed at intermediate and high 131 concentrations with a dearth at low doses ( Fig. 3C and D) . 132 133
Interaction type transitions. 134
Interaction types tend to transition from antagonism and additivity at low doses to synergy at 135 high doses for net three-way interaction, but to antagonism for emergent three-way 136 interaction. For both DA and E3, the magnitude of the mean of all antagonistic interactions and 137 the magnitude of the mean of all synergistic interactions each increase with the combined dose 138 of all three drugs (Fig. S2 , resulting in a dose dependency of interaction strength). We further 139
show net (DA) interactions are antagonistic at a low dose and shift to additivity or synergy at a 140 high dose (Fig. 4) . Most of the dose-dependent transitions are from additivity (no interaction) 141 to either synergy or antagonism. Transitions between synergy and antagonism-corresponding 142 to an extremely abrupt or sharp transition-are extremely rare, at less than 4% for DA and less 143 than 1% for E3. Antagonistic interactions remain antagonistic or transition to additivity more for 144 2-drug combinations (26%) than for 3-drug combinations (17%). Emergent interactions (E3) are 145 rarely synergistic. No drug combinations exhibit emergent synergy at the low dose (index 1), 146 while less than 4% do so at the high dose (index 6) (Fig. 4) . Interaction transitions are 147 summarized for each drug combination with both the sum and absolute change in DA (Fig. S3) . 148
Clearly, increasing the dose of one drug can lead to various trajectories for changes in DA ( predicts a more synergistic three-way DA, which is unsurprising, since the pairwise interactions 165 are included in the three-way DA. Although the relationship between three-way DA and E3 is 166 weak or non-existent, the anti-correlation between mean pairwise DA and E3 is striking. In 167 particular, for synergistic three-way DA (red points) interactions, there is a strong anti-168 correlation between pairwise DA and E3, indicating that antagonistic pairwise interactions tend 169 to be associated with strongly synergistic E3, which in turn drives the three-way interaction 170 synergistic (Fig. S6) . Conversely, when the mean of the three pairwise interactions is below zero 171 (corresponding to synergy) and the three-way DA is synergistic, E3 is predominantly 172
antagonistic. This effect is likely to result from low fitness at high doses that can cause large9 deviations in DA and E3. The correlations between pairwise DA, three-way DA, and E3 are 174 similar for both low and intermediate doses of the third drug (dose indices 2 and 4), with similar 175 correlation coefficients (Fig. S7) Meanwhile, 25 L of LB per well were prefilled into a second 384-well plates using the 295
Multidrop 384 (Thermo Scientific). Next, 500 nL from the source plate were delivered into the 296 prefilled plate using the Biomek FX (Beckman Coulter) with a pin tool (V&P Scientific). Then, 25 297 L of bacteria inoculum was added to each well to reach a final 50 L per well with 1% DMSO. 298 Each plate included negative controls (media alone), vehicle controls (media with 1% DMSO), 299 and positive controls (media with 1% DMSO and cells). The plates were incubated at 37C with 300 OD595 measurement for cell density at 4-hour intervals for 24 hours. IC50s were determined by 301 fitting a sigmoidal dose-response curve using the software Graphpad Prism. 302
303
Determining drug-dosage levels from dose-response curve of single drugs. 304
15
To establish reasonable resolutions of various drug doses, we designed our dilution regime (Fig.  305 2A) to cover a wide range of dose effectiveness in terms of bacterial fitness of lethal, low, 306 intermediate, and high. Mean dose response curves of each single drug (Fig. 2C) To increase our confidence and resolution of interaction transition with dose, given the fairly 377 noisy OD measurements, we smoothed the data using a weighted average algorithm by 378 considering our dose combination matrix as a metric space. For each data point (interaction 379 measurement at each drug-dose combination), both rescaled DA and E3 were recalculated as a 380 weighted average depending on the Euclidean distance (within the three-dimensional matrix) 381 between the original data point and the points used for calculation. The weight is 1 for the 382 origin, and 1/8d for the 26 nearest neighbors, where d is the Euclidean distance from the origin. 383
If a neighboring value was missing, either because it lies at the boundary or because it was 384 excluded due to low fitness, its weight was set to zero. The sum of the weights was required to 385 comprise at least 59 percent of the original weight matrix. we compared drug interaction of drug A at a sub-inhibitory concentration and drug B at either a 528 high dose and a low dose. In a three-drug combination, the interaction was examined with a 529 third drug at a high and low dose. Pairwise interactions (DA2, i.e. overall pairwise interaction) 530 are dominated by antagonism and additivity at the low dose (green and gray, 99%), while a 531 27 total of 10% are synergistic at the high dose (left). Three-way (DA) interactions are mostly 532 additive at the low dose (gray, 76%) and antagonistic (green, 22%), but change from additivity 533 to antagonism (16%) and from additivity or antagonism to synergy (21%) at the high dose. The 534 emergent three-way interactions measured by E3 are mainly additive at the low dose (gray, 535 89%) with the rest being antagonistic, and result in very few synergistic interactions at the high 536 dose (3%), with some being antagonistic (22%) and a majority being additive (75%). 
